ReviewAlcoholism, clinical and experimental research2015
Clinical impact of alcohol-related cirrhosis in the next decade: estimates based on current epidemiological trends in the United States.
Review in Alcoholism, clinical and experimental research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 86 citations in OpenAlex.
- Natural history and development of a novel composite endpoint in patients with alcohol-associated hepatitis: Data from a prospective multicenter study.Hepatology (Baltimore, Md.) · 2026Observational
- The impact of surging transplantation of alcohol-associated liver disease on transplantation for HCC and other indications.Hepatology communications · 2024Article
- Development and evaluation of objective trial performance metrics for multisite clinical studies: Experience from the AlcHep Network.Contemporary clinical trials · 2024Article
- Emergency services utilization by patients with alcohol-associated hepatitis: An analysis of national trends.Alcohol, clinical & experimental research · 2024Article
- A latent class analysis of alcohol-related problems among adults who drank in the past year.Journal of substance use · 2024Article
- Unveiling the effect of estrogen receptors in alcoholic liver disease: A novel outlook.Liver research (Beijing, China) · 2023Review
- Naltrexone for alcohol use disorder: Hepatic safety in patients with and without liver disease.Hepatology communications · 2022Article
- Trends and Outcomes of Alcoholic Liver Cirrhosis Hospitalizations in the Last Two Decades: Analysis of the Nationwide Inpatient Sample.Gastroenterology research · 2022Article
- Synergistic and Detrimental Effects of Alcohol Intake on Progression of Liver Steatosis.International journal of molecular sciences · 2022Review
- Impact of Sarcopenia and Myosteatosis in Non-Cirrhotic Stages of Liver Diseases: Similarities and Differences across Aetiologies and Possible Therapeutic Strategies.Biomedicines · 2022Review
- Acute Alcohol-Associated Hepatitis in the COVID-19 Pandemic - a Structured Review.Current transplantation reports · 2022Review
- Ethical and allocation issues in liver transplant candidates with alcohol related liver disease.Translational gastroenterology and hepatology · 2022Review
- Reducing the Global Burden of Alcohol-Associated Liver Disease: A Blueprint for Action.Hepatology (Baltimore, Md.) · 2021Review
- Activated Protein Phosphatase 2A Disrupts Nutrient Sensing Balance Between Mechanistic Target of Rapamycin Complex 1 and Adenosine Monophosphate-Activated Protein Kinase, Causing Sarcopenia in Alcohol-Associated Liver Disease.Hepatology (Baltimore, Md.) · 2021Article
- Compound Sarcopenia in Hospitalized Patients with Cirrhosis Worsens Outcomes with Increasing Age.Nutrients · 2021Article
- Identifying Quality Gaps in Preventive Care for Outpatients With Cirrhosis Within a Large, Academic Health Care System.Hepatology communications · 2020Article
- Skeletal muscle loss phenotype in cirrhosis: A nationwide analysis of hospitalized patients.Clinical nutrition (Edinburgh, Scotland) · 2020Article
- Elevated liver stiffness without histological evidence of liver fibrosis in rural Ugandans.Journal of viral hepatitis · 2020Article
- Design and rationale of a multicenter defeat alcoholic steatohepatitis trial: (DASH) randomized clinical trial to treat alcohol-associated hepatitis.Contemporary clinical trials · 2020Article
- Exercise and physical activity in cirrhosis: opportunities or perils.Journal of applied physiology (Bethesda, Md. : 1985) · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundIdentifying changes in the epidemiology of liver disease is critical for establishing healthcare priorities and allocating resources to develop therapies. The projected contribution of different etiologies toward development of cirrhosis in the United States was estimated based on current publications on epidemiological data and advances in therapy. Given the heterogeneity of published reports and the different perceptions that are not always reconcilable, a critical overview rather than a formal meta-analysis of the existing data and projections for the next decade was performed.
methodsData from the World Health Organization Global Status Report on Alcohol and Health of 2014, Scientific Registry of Transplant Recipients from 1999 to 2012, National Institute on Alcohol Abuse and Alcoholism, and the Centers for Disease Control and Prevention were inquired to determine future changes in the epidemiology of liver disease.
resultsAlcohol consumption has increased over the past 60 years. In 2010, transplant-related costs for liver recipients were the highest for hepatitis C (~$124 million) followed by alcohol-related cirrhosis (~$86 million). We anticipate a significant reduction in incidence cirrhosis due to causes other than alcohol because of the availability of high efficiency antiviral agents for hepatitis C, universal and effective vaccination for hepatitis B, relative stabilization of the obesity trends in the United States, and novel, potentially effective therapies for nonalcoholic steatohepatitis. The proportion of alcohol-related liver disease is therefore likely to increase in both the population as a whole and the liver transplant wait list.
conclusionsAlcohol-related cirrhosis and alcohol-related liver disorders will be the major cause of liver disease in the coming decades. There is an urgent need to allocate resources aimed toward understanding the pathogenesis of the disease and its complications so that effective therapies can be developed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.